Unit 2, 22nd Floor, Tower 6789, 6789 Ayala Avenue, Makati City

+63 28887 5160

YASUDA LOGISTICS AND EISAI ENTERS AGREEMENT TO TRANSFER EISAI’S SUBSIDIARY EISAI DISTRIBUTION TO YASUDA LOGISTICS

For Print (PDF)

Yasuda Logistics Corporation (Headquarters: Tokyo, CEO: Nobuyuki Fujii, “Yasuda Logistics”) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that they have entered into a share purchase agreement concerning the transfer of all shares of Eisai’s wholly-owned subsidiary Eisai Distribution Co., Ltd. (Headquarters: Kanagawa, “Eisai Distribution”) to Yasuda Logistics. The date of the share transfer is scheduled to be March 31, 2023.

Eisai Distribution was established in April 1991 as a wholly-owned subsidiary of Eisai and is mainly responsible for logistics-related operations for Eisai Group products, contributing to their stable supply, and has a wealth of experience and know-how specialized in pharmaceutical logistics with a large track record in handling third-party products.

Yasuda Logistics has formulated “Long-term Vision for 2030” that designs what the company should be in 2030, and in order to realize the long-term vision, Yasuda has formulated a Middle-term Management Plan “YASDA Next Challenge 2024”, aiming to build a business structure toward further growth. Yasuda Logistic Group believes that the integration of Eisai Distribution’s prescription drug delivery network with the company’s experience in warehouse operations will improve its medical logistics services, which is an important pillar of its growth strategy, as well as expanding the number of warehouses and other facilities, leading to the realization of higher quality medical logstics services than ever.

Eisai has been working on creating pharmaceutical products and solutions to contribute to patients and the people in the daily living domain with the vision of “empowering people to realize their fullest life.” With the business environment surrounding pharmaceuticals logistics undergoing significant changes, through this agreement Eisai will pursue a more stable and efficient supply of Eisai Group products and concentrate on select business areas. Eisai expects that the synergistic effect of Eisai Distribution entering into the Yasuda Logistics Group will lead to the company’s sustainable growth and further expansion, as well as even greater contributions to the stable supply of pharmaceutical products in Japan.

Eisai Distribution will continue to be responsible for logistics-related operations for Eisai Group products after April 1, 2023. A certain period of time will be set as the transition period, during which Eisai will provide Yasuda Logistics with the necessary support for continuation of Eisai Distribution’s business.

As a result of this transaction, Eisai anticipates no changes to its consolidated financial forecast for the period ended March 31, 2023. Yasuda Logistics also anticipates no changes to its consolidated financial forecast for the period ended March 31, 2023.

Media Inquiries

Yasuda Logistics Corporation Eisai Co., Ltd.

Corporate Planning, Operations Department
TEL:+81-(0)3-3452-7316

Public Relations Department
TEL:+81-(0)3-3817-5120

 

[Notes to editors]

1.  About Eisai Distribution

Company name: Eisai Distribution Co., Ltd.
Location: 1-16-2 Iiyama Minami, Atsugi, Kanagawa
Representative: Masayuki Miyajima, Representative Director and President
Scope of business: Distribution (warehousing, storage, delivery) of pharmaceuticals, diagnostics, investigational drugs, pharmaceutical raw materials, foods and food additives, etc., pharmaceutical manufacturing (packaging, labeling, storage), wholesale distribution, warehousing, others
Capital: 60 million JPY
Date established: April 1, 1991
Number of employees: 65 (as of March 31, 2022)

 

2.  About Yasuda Logistics Corporation
Since the establishment in 1919, Yasuda Logistics Corporation has grown its logistics business in scope from the Tokyo metropolitan area to encompass the whole of Japan, and strive to better meet the needs of customers through providing logistics services. Yasuda also directed its energy towards the real estate business early on, continuing to work towards its dream of a wealthier society through the activities of both businesses, a dream that is coming to fruition today.

In order to build a business structure for further growth, the Yasuda Logistics Group has formulated “Long-term Vision for 2030” that designs what we should be in 2030, states that “Through a fusion of the world-renowned YASDA brand and innovative technology, our goal is to become a group that surpasses the expectations of all stakeholders.”

In addition, Yasuda has identified “expansion and improvement of logistics centers, and strengthening service provision systems in medical logistics business” as key strategy of its Middle-term Management Plan for FY 2022 to FY 2024 “YASDA Next Challenge 2024”, and has positioned strengthening pharmaceutical logistics business as a key pillar of Yasuda’s growth strategy.

For more information about Yasuda, please visit https://www.yasuda-soko.co.jp .

3.  About Eisai Co., Ltd.
Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), Eisai aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, Eisai strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.

In addition, Eisai demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), with working on various activities together with global partners.

For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on Twitter @Eisai_SDGs

Our Values

Values are an integral part of our foundation. With every decision, we ensure that we follow:

Integrity

Integrity is the living up to legal, moral and ethical principles in the conduct of HI-Eisai Pharmaceutical Inc. business. It means that each employee embodies the value of integrity, and therefore represents the company in honesty and rectitude in all the ways they do their work.

It is expected that each employee would make decisions guided by good judgement, not just for one‘s self, but for HI-Eisai as the company. An employee who acts with integrity ensures that he has understanding of the principles by which the company operates, and in situations where he lacks clarity, will actively seek guidance.

Respect

The company is committed to ensure that it maintains a safe, inclusive, and healthy working environment that promotes productivity among employees. All employees are expected to show respect to fellow employees, customers, and patients, regardless of differences in gender, culture, backgrounds, and beliefs. Leaders in the organization are likewise expected to promote inclusivity with their teams, and shall not tolerate any discriminatory and offensive actions.

Accountability

Accountability at work means assuming responsibility for the business outcome and how that is achieved. It means that every employee, in whichever position, are equally responsible for the decisions and actions they make for the company. It is likewise, the responsibility of each employee to report, any knowledge of misconduct or potential violation to the company‘s rules and regulations.

Patient-Centric

At the heart of the company‘s operation are the patients. This means that every decision to be made, considers the potential impact and benefit to the patients. As such, the company commits itself in ensuring that business objectives align with its principle of human health care or hhc. The programs created and implemented are based on how well they could contribute to improving patients‘ lives.

For field-based employees, being patient-centric means that the focus of engagements with customers are on understanding patient needs as well as providing these stakeholders with comprehensive information on how HI-Eisai‘s products can support their patients goals.

For each employee, being patient-centric means taking on their responsibilities with care and consideration on how it impacts the patients experience, be it by making relevant information readily available for the doctors; or by ensuring access and availability to the medicines we offer.

Excellence

As a patient-centric company, we define Excellence by the outstanding quality of our work to improve patients‘ lives. Each employee is expected to consistently demonstrate work ethics that align to our values, policies, and our desire to provide above standard service. The company is committed in ensuring that all actions are in compliance with legal requirements.

Being excellent means that every employee passionately strives to be better and participates in the company‘s initiatives to develop their members in terms of knowledge, skills, and behavior, which will support a continuously improving, responsible and performance-driven workforce.

Our Vision

To be a successful and sustainable business in the Philippines by driving innovation and providing solutions to address unmet healthcare needs fueled by high-performing employees who deliver meaningful value and experience to patients and their families.

Our Mission

We give first thought to patients and their families, and to increasing the benefits health care provides.

Unit 2, 22nd Floor, Tower 6789, 6789 Ayala Avenue, Makati City

+63 28887 5160